FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130642925> ?p ?o ?g. }

• W3130642925 endingPage "1790" @default.
• W3130642925 startingPage "1781" @default.
• W3130642925 abstract "This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or –resistant) and the dosing regimen.This multicenter retrospective study enrolled children with difficult-to-treat nephrotic syndrome on rituximab treatment from 13 centers. The patients were classified based on low (single dose of 375 mg/m2) or high (2-4 doses of 375 mg/m2) initial dose of rituximab and the steroid response. Clinical outcomes were compared.Data from 42 children [20 steroid-sensitive (frequent relapsing / steroid-dependent) and 22 steroid-resistant nephrotic syndrome, aged 1.9–17.3 years] were analyzed. Eleven patients with steroid-sensitive nephrotic syndrome (55%) had a relapse following initial rituximab therapy, with the mean time to first relapse of 8.4 ± 5.2 months. Complete remission was achieved in 41% and 36% of steroid-resistant patients, with the median remission time of 3.65 months. At Year 2, eight patients in steroid-sensitive group (40%) and four in steroid-resistant group (18%) were drug-free. Total cumulative doses of rituximab were higher in steroid-resistant group (p = 001). Relapse rates and time to first relapse in steroid-sensitive group or remission rates in steroid-resistant group did not differ between the low and high initial dose groups.The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined." @default.
• W3130642925 created "2021-03-01" @default.
• W3130642925 creator A5000078882 @default.
• W3130642925 creator A5008945993 @default.
• W3130642925 creator A5015756255 @default.
• W3130642925 creator A5023157532 @default.
• W3130642925 creator A5025081223 @default.
• W3130642925 creator A5026566017 @default.
• W3130642925 creator A5029242235 @default.
• W3130642925 creator A5037691758 @default.
• W3130642925 creator A5040900876 @default.
• W3130642925 creator A5041260626 @default.
• W3130642925 creator A5043012855 @default.
• W3130642925 creator A5047907071 @default.
• W3130642925 creator A5070227822 @default.
• W3130642925 creator A5077817615 @default.
• W3130642925 creator A5081328524 @default.
• W3130642925 creator A5083026258 @default.
• W3130642925 creator A5087971689 @default.
• W3130642925 creator A5089724010 @default.
• W3130642925 creator A5090949228 @default.
• W3130642925 date "2021-08-30" @default.
• W3130642925 modified "2023-10-12" @default.
• W3130642925 title "Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study" @default.
• W3130642925 doi "https://doi.org/10.3906/sag-2012-297" @default.
• W3130642925 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8569731" @default.
• W3130642925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33581711" @default.
• W3130642925 hasPublicationYear "2021" @default.
• W3130642925 type Work @default.
• W3130642925 sameAs 3130642925 @default.
• W3130642925 citedByCount "2" @default.
• W3130642925 countsByYear W31306429252022 @default.
• W3130642925 countsByYear W31306429252023 @default.
• W3130642925 crossrefType "journal-article" @default.
• W3130642925 hasAuthorship W3130642925A5000078882 @default.
• W3130642925 hasAuthorship W3130642925A5008945993 @default.
• W3130642925 hasAuthorship W3130642925A5015756255 @default.
• W3130642925 hasAuthorship W3130642925A5023157532 @default.
• W3130642925 hasAuthorship W3130642925A5025081223 @default.
• W3130642925 hasAuthorship W3130642925A5026566017 @default.
• W3130642925 hasAuthorship W3130642925A5029242235 @default.
• W3130642925 hasAuthorship W3130642925A5037691758 @default.
• W3130642925 hasAuthorship W3130642925A5040900876 @default.
• W3130642925 hasAuthorship W3130642925A5041260626 @default.
• W3130642925 hasAuthorship W3130642925A5043012855 @default.
• W3130642925 hasAuthorship W3130642925A5047907071 @default.
• W3130642925 hasAuthorship W3130642925A5070227822 @default.
• W3130642925 hasAuthorship W3130642925A5077817615 @default.
• W3130642925 hasAuthorship W3130642925A5081328524 @default.
• W3130642925 hasAuthorship W3130642925A5083026258 @default.
• W3130642925 hasAuthorship W3130642925A5087971689 @default.
• W3130642925 hasAuthorship W3130642925A5089724010 @default.
• W3130642925 hasAuthorship W3130642925A5090949228 @default.
• W3130642925 hasBestOaLocation W31306429251 @default.
• W3130642925 hasConcept C126322002 @default.
• W3130642925 hasConcept C167135981 @default.
• W3130642925 hasConcept C187212893 @default.
• W3130642925 hasConcept C2777747828 @default.
• W3130642925 hasConcept C2777785397 @default.
• W3130642925 hasConcept C2778415529 @default.
• W3130642925 hasConcept C2778930706 @default.
• W3130642925 hasConcept C2779338263 @default.
• W3130642925 hasConcept C2780091579 @default.
• W3130642925 hasConcept C2780368995 @default.
• W3130642925 hasConcept C2780653079 @default.
• W3130642925 hasConcept C2780902042 @default.
• W3130642925 hasConcept C2781413609 @default.
• W3130642925 hasConcept C71315377 @default.
• W3130642925 hasConcept C71924100 @default.
• W3130642925 hasConcept C90924648 @default.
• W3130642925 hasConceptScore W3130642925C126322002 @default.
• W3130642925 hasConceptScore W3130642925C167135981 @default.
• W3130642925 hasConceptScore W3130642925C187212893 @default.
• W3130642925 hasConceptScore W3130642925C2777747828 @default.
• W3130642925 hasConceptScore W3130642925C2777785397 @default.
• W3130642925 hasConceptScore W3130642925C2778415529 @default.
• W3130642925 hasConceptScore W3130642925C2778930706 @default.
• W3130642925 hasConceptScore W3130642925C2779338263 @default.
• W3130642925 hasConceptScore W3130642925C2780091579 @default.
• W3130642925 hasConceptScore W3130642925C2780368995 @default.
• W3130642925 hasConceptScore W3130642925C2780653079 @default.
• W3130642925 hasConceptScore W3130642925C2780902042 @default.
• W3130642925 hasConceptScore W3130642925C2781413609 @default.
• W3130642925 hasConceptScore W3130642925C71315377 @default.
• W3130642925 hasConceptScore W3130642925C71924100 @default.
• W3130642925 hasConceptScore W3130642925C90924648 @default.
• W3130642925 hasIssue "4" @default.
• W3130642925 hasLocation W31306429251 @default.
• W3130642925 hasLocation W31306429252 @default.
• W3130642925 hasLocation W31306429253 @default.
• W3130642925 hasOpenAccess W3130642925 @default.
• W3130642925 hasPrimaryLocation W31306429251 @default.
• W3130642925 hasRelatedWork W1589180913 @default.
• W3130642925 hasRelatedWork W1765855 @default.
• W3130642925 hasRelatedWork W1983663249 @default.
• W3130642925 hasRelatedWork W2038400827 @default.
• W3130642925 hasRelatedWork W2042732525 @default.
• W3130642925 hasRelatedWork W2885165956 @default.

• next